TEL AVIV, Israel, September 10, 2012 /PRNewswire/ --



Maxillent Ltd., a company dedicated to innovative solutions for dental implants, has signed an exclusive contract with Pioneer Richteeth Medical Distribution Company Shanghai Ltd. for the distribution of the iRaise™ Sinus Lift Implant in Hong Kong. The pre-launch event for iRaise was hosted jointly by Maxillent and Pioneer in the Hong Kong Dental Implant Surgical Center (DISC) on August 31, 2012.

iRaise solves a key difficulty in implant surgery: the highly invasive and traumatic sinus lift procedure, required in 20% of dental implant cases, when there is insufficient bone in the upper jaw to support implants. The current sinus lift procedure requires over an hour of invasive surgery, and causes significant trauma: patients require three to ten days of home rest, and complain of significant swelling and bruising.

iRaise™ provides a minimally invasive alternative to the sinus lift. The technology is based on a unique dental implant with an internal channel, which allows the dentist to perform a sinus lift using a simple hydraulic method. For the dentist, the procedure significantly reduces chair time, complications, and post-operative care. For patients, iRaise offers vastly reduced discomfort and recovery time, eliminates facial swelling and bruising, and prevents lost work days.

"We are excited to expand the availability of iRaise to APAC markets," says Gideon Fostick, CEO of Maxillent. "We have chosen Pioneer as the ideal partner for our first entry into Asia. They have the expertise and reach we were looking for in Hong Kong and in additional Asian markets."

"Maxillent's technology for minimally invasive sinus lifts is very well suited to the Hong Kong market, where dentists want to provide patients with the best possible experience," says Vincent Yuen, Managing Director, Pioneer Dental Division.

About Maxillent

Maxillent was founded in 2008 by Rainbow Medical, an Israeli company dedicated to developing medical device companies with breakthrough therapeutic technologies.  Maxillent reached clinical trials within a year from inception. Three years of clinical experience in Europe and Israel have exhibited an excellent safety and efficacy profile. Following CE Mark approval in 2011, the company recently launched the iRaise commercially in Israel and several European countries. Maxillent's  Scientific Advisory Board comprises key opinion leaders, such as Prof.David L Cochran from San Antonio Texas, Prof. Donald Clem from California, and Prof. Gabriel Chaushu from Israel. For more, visit: http://www.maxillent.com

For more information, please contact:
Josh Turner
Media Relations
+972-54-949-6526
josh@joshturnerpr.com

SOURCE Maxillent Ltd